7855217

19 known cases. View patent page →

Cases
19
Active
1
18 closed
Filed
2016–2020
Top venue
D. New Jersey
7 cases

Filing activity

2016: 2 cases'162017: 3 cases3'172018: 3 cases'18'192020: 2 cases'20
Cases asserting US Patent 7855217 filed per year.

Celgene Corporation v. Zydus Pharmaceuticals (USA) Inc. et al.

settled
Docket:
2:17-cv-02528
Filed:
2017-04-12
Terminated:
2021-03-24

Celgene sued Zydus/Cadila/Zydus International for patent infringement under 35 U.S.C. § 271(e)(2) in D.N.J. The case asserted multiple lenalidomide patents including 8,648,095. Consent judgment entered 2021-03-24 dismissing with prejudice pursuant to settlement.

Celgene Corporation v. Dr. Reddy's Laboratories, Ltd. et al.

settled
Docket:
2:16-cv-07704
Filed:
2016-10-20
Terminated:
2020-09-17

Patent infringement action involving ANDA No. 209348; complaint expressly alleged infringement of the '800, '217, '569, '498, '095, '621 and '622 patents. Settled September 17, 2020 with volume-limited license from September 1, 2022 and unlimited from January 31, 2026.

Blue Cross Blue Shield Association plaintiffs v. Celgene Corporation et al.

Antitrust action by Blue Cross Blue Shield Association plaintiffs against Celgene/BMS concerning Revlimid settlements; patents cited include the same Revlimid patent set as the In re Revlimid litigation.

Celgene Corp. v. Dr. Reddy's Laboratories, Inc.

settled
Filed:
2016-10-20
Terminated:
2020-09-17
Patents:7855217

Celgene sued Dr. Reddy's Laboratories in D.N.J. over generic lenalidomide, with U.S. 7,855,217 among the asserted patents. The case settled, and a consent judgment was entered on September 17, 2020, with Dr. Reddy's agreeing not to market generic Revlimid until expiration of the asserted patents. The docket number was not directly confirmed in the narrative.

Celgene Corp. v. Lotus Pharmaceutical Co., Ltd. et al.

consent judgment
Docket:
2:17-cv-06842
Filed:
2017-09-06
Terminated:
2019-03-29
Patents:7855217

Celgene sued Lotus Pharmaceutical and Alvogen Pine Brook in D.N.J. (2:17-cv-06842), with U.S. 7,855,217 among the patents-in-suit. A consent judgment was entered on March 29, 2019, after Celgene withdrew an earlier covenant not to sue on '217.

Celgene Corp. v. Mylan Pharmaceuticals Inc. et al.

settled
Docket:
1:20-cv-00003
Filed:
2020-01-03
Terminated:
2021-07-23
Patents:7855217

Celgene sued Mylan Pharmaceuticals, Mylan Inc., and Mylan N.V. in the Northern District of West Virginia (1:20-cv-00003), asserting U.S. 7,855,217 among other patents. The case settled on July 21, 2021, and terminated July 23, 2021 (ANDA No. 213912).

Celgene Corp. v. Aurobindo Pharma Ltd. et al.

settled
Docket:
2:20-cv-00315
Filed:
2020-01-08
Terminated:
2021-07-19
Patents:7855217

Celgene sued Aurobindo entities in D.N.J. (2:20-cv-00315), asserting U.S. 7,855,217 among other patents. The case settled on July 15, 2021, and terminated July 19, 2021 (ANDA No. 213885).